Rakovina Therapeutics Inc. (TSXV: RKV)

Market Cap	17.61M
Revenue (ttm)	n/a
Net Income (ttm)	-3.31M
Shares Out	90.29M
EPS (ttm)	-0.04
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	200,977
Average Volume	257,258
Open	0.210
Previous Close	0.190
Day's Range	0.185 - 0.215
52-Week Range	0.005 - 0.215
Beta	-0.62
RSI	61.10
Earnings Date	Apr 25, 2025

About Rakovina Therapeutics

Rakovina Therapeutics Inc., a biopharmaceutical research company, engages in the research and development of cancer treatments based on novel series of small-molecule DNA-damage response targets. Its preclinical product pipeline include kt-2000AI, an poly(ADP)-ribose polymerase (PARP) brain penetrant cancer therapy; kt-3000, a bi-functional small-molecule drug candidate; kt-3283 series for the treatment of PARP resistant adult and childhood cancers; and kt-4000, a DNA-damaging DDR inhibitors. It has a research collaboration with Variational AI ...

• Industry: Biotechnology
• Sector: Healthcare
• CEO: Mads Daugaard
• Country: Canada
• Stock Exchange: TSX Venture Exchange
• Ticker Symbol: RKV